COMMUNIQUÉS West-GlobeNewswire

IBA – ACQUISITION D’ACTIONS PROPRES
15/06/2026
Louvain-la-Neuve, Belgique, 15 juin 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
15/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 15 June 2026 at 16.15 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
SafeSpace Global Appoints Michael Hrynuik as Chief Financial Officer
15/06/2026
Veteran Capital Markets and Corporate Finance Executive to Lead Financial Strategy for Revenue-Generating, AI-powered Physical Safety Platform NASHVILLE, TN., June 15, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global [...]
Wildfire Smoke Reaches Record Levels as Americans Struggle to Breathe
15/06/2026
Betterbrand's BetterLungs supplement supports respiratory health naturally as wildfire season intensifies across the U.S. SAN ANTONIO, TX, June 15, 2026 (GLOBE NEWSWIRE) -- Wildfire Smoke Reaches Record Levels as [...]
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
15/06/2026
Company announcement No. 25 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 24, 2026) Copenhagen, Denmark, June 15, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026
Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward Improved Profitability CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2026
15/06/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 8 juin au 12 juin 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
France Biotech to Showcase the Strength and Global Momentum of French HealthTech at BIO International Convention 2026 in San Diego
15/06/2026
Meet France Biotech and the French delegation at BIO International Convention 2026 – French Pavilion #3325. France Biotech to Showcase the Strength and Global Momentum of French HealthTech at BIO International [...]
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
15/06/2026
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany [...]
10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
15/06/2026
As global soccer fever builds, 10 Barrel Brewing and Pub Beer are bringing fans together across the Pacific Northwest with watch parties, game-day limited-edition merch and activations, sweepstakes and more BEND, Ore., [...]
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
15/06/2026
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
15/06/2026
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+ [...]
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
15/06/2026
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T [...]
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
15/06/2026
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets JUPITER, [...]
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
15/06/2026
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical [...]
Kraig Biocraft Laboratories CEO Kim Thompson Highlights Commercial Scale, Competitive Advantages, and the Future of Spider Silk in Featured Pulse 2.0 Interview
15/06/2026
Company's Founder Details Production Growth, Industry Transformation Strategy, and Expanding Commercial Opportunities for Recombinant Spider Silk ANN ARBOR, Mich., June 15, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft [...]
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
15/06/2026
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
15/06/2026
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months [...]
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
15/06/2026
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are [...]

Pages